Intraocular Pressure Change Following Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agent
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- Change from baseline in intraocular pressure
研究概览
简要总结
The introduction of additional fluid into the vitreous cavity by intravitreal therapy would be expected to cause an immediate rise in the intraocular pressure. This transient, short-term intraocular pressure elevation (lasting up to 30 minutes) after intravitreal anti-vascular endothelial growth factor therapy has been well describe. The investigators aim to study the prevalence of the sustained intraocular pressure elevation associated with intravitreal injection of anti-vascular endothelial growth factor agents.
详细描述
Intravitreal injections of anti-vascular endothelial growth factor agents are commonly used to treat a variety of retinal and choroidal neovascular diseases. The introduction of additional fluid into the vitreous cavity by intravitreal therapy would be expected to cause an immediate rise in the intraocular pressure.
Although there is one study showed no significant changes in the intraocular pressure many retrospective studies showed the impacts on the intraocular pressure elevation. The investigators aim to prospective evaluate the intraocular pressure change in non-glaucomatous patients receiving an intravitreal anti-vascular endothelial growth factor therapy.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients scheduled to receive intravitreal injection of anti-vascular endothelial growth factor agent (either bevacizumab or ranibizumab), and
- •Age of 18-85 year-old, and
- •Initial intraocular pressure < 21 mmHg
排除标准
- •Diagnosis of open angle, or
- •Diagnosis of angle-closure glaucoma, or
- •Diagnosis of glaucoma suspect (intraocular pressure > 21 mmHg on 2-consecutive visit and/or cup to disc ratio > 0.5) , or
- •Currently receive systemic beta-blocker
- •Previously received intravitreal injection of anti-vascular endothelial growth factor agent
- •Previously received intravitreal injection of steroid or gancyclovir
- •Current use of steroid eye drop
- •Any ocular surface disease preclude a reliable intraocular pressure measurement
结局指标
主要结局
Change from baseline in intraocular pressure
时间窗: 6-month after injection
intraocular pressure change at 6-month after injection
次要结局
- Number of anti-glaucoma used(6-month)
研究者
Weerawat Kiddee
Asst. Prof.
Prince of Songkla University